克立硼罗在皮肤科的应用进展
Application Progress of Crisaborole in Dermatology
DOI: 10.12677/ACM.2022.125709, PDF,   
作者: 陈辅琼：青海大学研究生院，青海 西宁；郭 砚：青海大学附属医院皮肤病与性病科，青海 西宁
关键词: PDE-4抑制剂；克立硼罗软膏；皮肤性疾病；治疗；PDE-4 Inhibitors； Crisaborole Ointment； Dermatogic Disease； Treatment
摘要: 目的：综述磷酸二酯酶-4抑制剂克立硼罗软膏(Crisaborole)在治疗皮肤性疾病中的研究进展。方法：查阅近5年国内外文献27篇，对其进行归纳、分析和总结。结果：新型磷酸二酯酶-4抑制剂克立硼罗通过抑制磷酸二酯酶-4，增加细胞内cAMP水平，继而减少体内炎症因子的合成，在特应性皮炎、银屑病等炎性皮肤病方面作用显著。目前，克立硼罗已获得中国国家药监局批准，用于2岁以上轻中度特应性皮炎患者的治疗，商品名为舒坦明。结论：克立硼罗软膏作为新型磷酸二酯酶-4抑制剂，在皮肤性疾病中应用广泛，具有良好的发展前景及探究意义。
Abstract: Objective: To review the research progress of phosphodiesterase-4 inhibitor Crisaborole ointment in the treatment of skin diseases. Methods: 27 literatures at home and abroad in recent 5 years were reviewed and summarized. Results: The new phosphodiesterase-4 inhibitor, criboro, in-creased intracellular cAMP level by inhibiting phosphodiesterase-4, thereby reducing the synthesis of inflammatory factors in vivo, and played a significant role in inflammatory skin diseases such as atopic dermatitis and psoriasis. At present, crisaborole has been approved by the State Administra-tion of Drugs of China for the treatment of patients over 2 years old with mild to moderate atopic dermatitis, and the commodity name is Shutanming. Conclusion: Crisaborole ointment, as a new phosphodiesterase-4 inhibitor, is widely used in skin diseases and has good development prospects and exploration significance.
文章引用：陈辅琼, 郭砚. 克立硼罗在皮肤科的应用进展[J]. 临床医学进展, 2022, 12(5): 4891-4896. https://doi.org/10.12677/ACM.2022.125709

参考文献

[1] Zane, L.T., Chanda, S., Jarnagin, K., et al. (2016) Crisaborole and Its Potential Role in Treating Atopic Dermatitis: Over-view of Early Clinical Studies. Immunotherapy, 8, 853-866. [Google Scholar] [CrossRef] [PubMed]
[2] Hanifin, J.M., Chan, S.C., Cheng, J.B., et al. (1996) Type 4 Phosphodiesterase Inhibitors Have Clinical and in Vitro An-ti-Inflammatory Effects in Atopic Dermatitis. Journal of Investigative Dermatology, 107, 51-56. [Google Scholar] [CrossRef] [PubMed]
[3] Nutten, S. (2015) Atopic Dermatitis: Global Epidemiology and Risk Factors. Annals of Nutrition and Metabolism, 66, 8-16. [Google Scholar] [CrossRef] [PubMed]
[4] Cheape, A.C. and Murrell, D.F. (2017) 2% Crisaborole Topical Ointment for the Treatment of Mild-to-Moderate Atopic Dermati-tis. Expert Review of Clinical Immunology, 13, 415-423. [Google Scholar] [CrossRef] 
[5] Guttman-Yassky, E., Hanifin, J.M., Boguniewicz, M., et al. (2019) The Role of Phosphodiesterase 4 in the Pathophysiology of Atopic Dermatitis and the Perspective for Its Inhibi-tion. Experimental Dermatology, 28, 3-10. [Google Scholar] [CrossRef] [PubMed]
[6] Li, H., Zuo, J. and Tang, W. (2018) Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. Frontiers in Pharmacology, 9, Article No. 1048. [Google Scholar] [CrossRef] [PubMed]
[7] Zane, L.T., Hughes, M.H. and Shakib, S. (2016) Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled Study in Healthy Volunteers. American Journal of Clinical Dermatology, 17, 519-526. [Google Scholar] [CrossRef] [PubMed]
[8] Zane, L.T., Kircik, L., Call, R., et al. (2016) Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open-Label, Maximal-Use Systemic Exposure Study. Pediatric Dermatology, 33, 380- 387. [Google Scholar] [CrossRef] [PubMed]
[9] Stein Gold, L.F., Spelman, L., Spellman, M.C., et al. (2015) A Phase 2, Randomized, Controlled, Dose-Ranging Study Evaluating Crisaborole Topical Ointment, 0.5% and 2% in Adolescents with Mild to Moderate Atopic Dermatitis. Journal of Drugs in Dermatology, 14, 1394-1399.
[10] Eichenfield, L.F., Call, R.S., Forsha, D.W., et al. (2017) Long-Term Safety of Crisaborole Ointment 2% in Children and Adults with Mild to Moderate Atopic Dermatitis. Journal of the American Academy of Dermatology, 77, 641- 649.E5. [Google Scholar] [CrossRef] [PubMed]
[11] Schlessinger, J., Shepard, J.S., Gower, R., et al. (2020) Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to <24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1). American Journal of Clinical Dermatology, 21, 275-284. [Google Scholar] [CrossRef] [PubMed]
[12] 林杨杨, 廉佳, 宫泽琨, 卞亚伟, 刘欣欣, 毕田田, 王莹, 冯小燕, 李钦峰. 克立硼罗软膏治疗儿童轻中度特应性皮炎65例疗效观察[J]. 中国实用儿科杂志, 2021, 36(9): 693-696.
[13] Choudhary, S., Pradhan, D., Khan, N.S., et al. (2020) De-coding Psoriasis: Integrated Bioinformatics Approach to Understand Hub Genes and Involved Pathways. Current Pharmaceutical Design, 26, 3619-3630. [Google Scholar] [CrossRef] [PubMed]
[14] Cannavò, S.P., Riso, G., Casciaro, M., et al. (2019) Oxidative Stress Involvement in Psoriasis: A Systematic Review. Free Radical Research, 53, 829-840. [Google Scholar] [CrossRef] [PubMed]
[15] Orlik, C., Deibel, D., Küblbeck, J., et al. (2020) Keratino-cytes Costimulate Naive Human T Cells via CD2: A Potential Target to Prevent the Development of Proinflammatory Th1 Cells in the Skin. Cellular & Molecular Immunology, 17, 380-394. [Google Scholar] [CrossRef] [PubMed]
[16] Hashim, P.W., Chima, M., Kim, H.J., et al. (2020) Crisaborole 2% Ointment for the Treatment of Intertriginous, Anogenital, and Facial Psoriasis: A Double-Blind, Randomized, Vehi-cle-Controlled Trial. Journal of the American Academy of Dermatology, 82, 360-365. [Google Scholar] [CrossRef] [PubMed]
[17] Liu, Y.Y. and Li, W. (2022) Successful Treatment with Crisabo-role for Facial Lesions Refractory to Adalimumab in a Man with Psoriasis: A Case Report. Dermatologic Therapy, 35, e15424. [Google Scholar] [CrossRef] [PubMed]
[18] Nagui, N., Gaballah, B., Rashed, L. and Sany, I. (2021) Evaluation of Phosphodiesterase 4 Enzyme Levels in Lesional Skin and Serum of Vitiligo Patients. Journal of the Egyptian Wom-en’s Dermatologic Society, 18, 186-190. [Google Scholar] [CrossRef] 
[19] Tam, I., Kahn, J.S. and Rosmarin, D. (2021) Repigmentation in a Patient with Vitiligo on Crisaborole 2% Ointment. JAAD Case Reports, 11, 99-101. [Google Scholar] [CrossRef] [PubMed]
[20] Robbins, A.B., Gor, A. and Bui, M.R. (2018) Topical Crisaboro-le—A Potential Treatment for Recalcitrant Palmoplantar Psoriasis. JAMA Dermatology, 154, 1096-1097. [Google Scholar] [CrossRef] [PubMed]
[21] Wei, G., Rodriguez-Waitkus, P. and Soylu, L. (2021) A Rare Case of Lichen Simplex Chronicus in an Adolescent Female Successfully Managed with Crisaborole. Dermatologic Therapy, 34, e14752. [Google Scholar] [CrossRef] [PubMed]
[22] Barney, E., Prose, N.S. and Ramirez, M. (2019) In-flammatory Linear Verrucous Epidermal Nevus Treated Successfully with Crisaborole Ointment in a 5-Year-Old Boy. Pediatric Dermatology, 36, 404-405. [Google Scholar] [CrossRef] [PubMed]
[23] Henning, C., Meyers, S., Swift, R., Eades, B., Bussell, L., Spektor, T.M. and Berenson, J.R. (2020) Efficacy of Topical Use Crisaborole 2% Ointment for Treatment of Necrobiotic Xanthogranu-loma Associated with Multiple Myeloma. Clinical Lymphoma, Myeloma and Leukemia, 20, E492-E495. [Google Scholar] [CrossRef] [PubMed]
[24] Keren, A., Shemer, A., Ullmann, Y., et al. (2015) The PDE4 In-hibitor, Apremilast, Suppresses Experimentally Induced Alopecia Areata in Human Skin in Vivo. Journal of Dermato-logical Science, 77, 74-76. [Google Scholar] [CrossRef] [PubMed]
[25] Taneja, N. and Gupta, S. (2020) Apremilast Is Efficacious in Refractory Alopecia Areata. Journal of Dermatological Treatment, 31, 727-729. [Google Scholar] [CrossRef] [PubMed]
[26] 张帆, 糜自豪, 孙勇虎. 外用磷酸二酯酶4抑制剂软膏治疗斑秃一例附文献复习[J]. 中国麻风皮肤病杂志, 2022, 38(4): 217-219.

为你推荐